Literature DB >> 2826650

Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization.

L Banks1, G Matlashewski, D Pim, M Churcher, C Roberts, L Crawford.   

Abstract

The L1 and L2 capsid proteins encoded by human papillomavirus types 6 and 16 (HPV-6 and HPV-16) have been synthesized in bacteria. Antisera were raised against the HPV-6 L1- and L2-beta-galactosidase fusion proteins and against an HPV-16 L1 C-terminal peptide which was 14 amino acids long. The HPV-16 L1 peptide antibodies have been shown to be highly reactive with the HPV-16 L1-beta-galactosidase protein but not against the equivalent HPV-6 L1-beta-galactosidase fusion protein. The effectiveness of these antibodies was compared with commercially available antibovine papillomavirus type 1 (BPV-1) antibodies and the results demonstrated that the anti-BPV-1 antibodies reacted well against HPV-6 L1-beta-galactosidase but not against HPV-16 L1-beta-galactosidase. In addition, the L2 portion of the HPV-6 L2-beta-galactosidase fusion protein appeared particularly immunogenic, since antibodies raised against this fusion protein were predominantly reactive with the L2 moiety. The HPV-16 L1 peptide antibodies described here will be preferred reagents for the specific detection of HPV-16 capsid antigens, which may be particularly important in early diagnosis of HPV-16 infection.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2826650     DOI: 10.1099/0022-1317-68-12-3081

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  7 in total

1.  Simultaneous in situ genotyping and phenotyping of human papillomavirus cervical lesions: comparative sensitivity and specificity.

Authors:  A K Graham; C S Herrington; O McGee J
Journal:  J Clin Pathol       Date:  1991-02       Impact factor: 3.411

2.  Human antibodies react with an epitope of the human papillomavirus type 6b L1 open reading frame which is distinct from the type-common epitope.

Authors:  S A Jenison; X P Yu; J M Valentine; D A Galloway
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  Immunization with a pentameric L1 fusion protein protects against papillomavirus infection.

Authors:  H Yuan; P A Estes; Y Chen; J Newsome; V A Olcese; R L Garcea; R Schlegel
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

4.  Antigenic and immunogenic epitopes shared by human papillomavirus type 16 and bovine, canine, and avian papillomaviruses.

Authors:  L Dillner; P Heino; J Moreno-Lopez; J Dillner
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

5.  Human papillomavirus type 16 infection of the cervix: a comparison of differing DNA detection modes and the use of monoclonal antibodies against the major capsid protein.

Authors:  C J Lacey; M Wells; R I Macdermott; P E Gibson
Journal:  Genitourin Med       Date:  1991-04

6.  Characterization of Lactococcus lactis phage antigens.

Authors:  C Schouler; C Bouet; P Ritzenthaler; X Drouet; M Mata
Journal:  Appl Environ Microbiol       Date:  1992-08       Impact factor: 4.792

7.  N-terminal truncations on L1 proteins of human papillomaviruses promote their soluble expression in Escherichia coli and self-assembly in vitro.

Authors:  Minxi Wei; Daning Wang; Zhihai Li; Shuo Song; Xianglin Kong; Xiaobing Mo; Yurou Yang; Maozhou He; Zhongyi Li; Bo Huang; Zhijie Lin; Huirong Pan; Qingbing Zheng; Hai Yu; Ying Gu; Jun Zhang; Shaowei Li; Ningshao Xia
Journal:  Emerg Microbes Infect       Date:  2018-09-26       Impact factor: 7.163

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.